Thursday, October 30, 2025 10/30/2025

Development of Inhibitors of cANGPTL4 for Pancreatic Cancer Therapeutics

Award Number: R43CA232844
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

Development of Inhibitors of cANGPTL4 for Pancreatic Cancer Therapeutics - This project seeks to develop inhibitors of a novel pancreatic ductal adenocarcinoma (PDAC) protein target. PDAC remains one of the deadliest cancers with an average survival of 3.5 months for non-resectable tumors. Currently, a major obstacle in PDAC treatment is that the cells rapidly exhibit resistance to existing untargeted treatment regimens leaving patients with no further options. Studies indicate that inhibiting this novel protein target will be effective against the most severe forms of PDAC. Aim 1 of this project will expand and refine the inhibitor chemotype using computational and experimental binding measurements. Aim 2 will experimentally validate the hits from Aim 1 and assess specificity and mechanism of action of hit compounds in vitro. Finally, preliminary ADME will be assessed on the top hits. During Phase II, these data will drive medicinal chemistry design and synthesis of a lead series. Followed by in vivo toxicity, pharmacokinetics, and efficacy producing a validated and targeted PDAC therapeutic lead compound for further pre-clinical studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	CFD RESEARCH CORP	6820 MOQUIN DR NW	HUNTSVILLE	AL	35806	MADISON	USA	Cancer Treatment Research	000	1	1/28/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $300,000 )
2019	2019	CFD RESEARCH CORPORATION	701 MCMILLIAN WAY STE D	HUNTSVILLE	AL	35806	MADISON	USA	Cancer Treatment Research	000	1	9/19/2019	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $300,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Inhibitors of cANGPTL4 for Pancreatic Cancer Therapeutics

Award Number: R43CA232844

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer